全文获取类型
收费全文 | 5123篇 |
免费 | 534篇 |
国内免费 | 71篇 |
专业分类
耳鼻咽喉 | 47篇 |
儿科学 | 41篇 |
妇产科学 | 18篇 |
基础医学 | 95篇 |
口腔科学 | 13篇 |
临床医学 | 3823篇 |
内科学 | 117篇 |
皮肤病学 | 5篇 |
神经病学 | 654篇 |
特种医学 | 24篇 |
外科学 | 13篇 |
综合类 | 228篇 |
预防医学 | 48篇 |
眼科学 | 55篇 |
药学 | 326篇 |
1篇 | |
中国医学 | 219篇 |
肿瘤学 | 1篇 |
出版年
2024年 | 14篇 |
2023年 | 139篇 |
2022年 | 131篇 |
2021年 | 203篇 |
2020年 | 248篇 |
2019年 | 185篇 |
2018年 | 138篇 |
2017年 | 184篇 |
2016年 | 176篇 |
2015年 | 174篇 |
2014年 | 220篇 |
2013年 | 279篇 |
2012年 | 175篇 |
2011年 | 203篇 |
2010年 | 157篇 |
2009年 | 231篇 |
2008年 | 262篇 |
2007年 | 236篇 |
2006年 | 271篇 |
2005年 | 231篇 |
2004年 | 193篇 |
2003年 | 173篇 |
2002年 | 176篇 |
2001年 | 135篇 |
2000年 | 113篇 |
1999年 | 130篇 |
1998年 | 111篇 |
1997年 | 111篇 |
1996年 | 97篇 |
1995年 | 91篇 |
1994年 | 87篇 |
1993年 | 75篇 |
1992年 | 75篇 |
1991年 | 61篇 |
1990年 | 29篇 |
1989年 | 23篇 |
1988年 | 25篇 |
1987年 | 21篇 |
1986年 | 31篇 |
1985年 | 29篇 |
1984年 | 23篇 |
1983年 | 15篇 |
1982年 | 17篇 |
1981年 | 18篇 |
1980年 | 7篇 |
1979年 | 3篇 |
1978年 | 1篇 |
1977年 | 1篇 |
排序方式: 共有5728条查询结果,搜索用时 15 毫秒
91.
Case Report of the Safety Assessment of Transcranial Magnetic Stimulation Use in a Patient With Cardiac Pacemaker: To Pulse or Not to Pulse?
下载免费PDF全文
![点击此处可从《Headache》网站下载免费的PDF全文](/ch/ext_images/free.gif)
92.
93.
94.
Measures of Functioning in Patients With Episodic Migraine: Findings From a Double‐Blind,Randomized, Placebo‐Controlled Phase 2b Trial With Galcanezumab
下载免费PDF全文
![点击此处可从《Headache》网站下载免费的PDF全文](/ch/ext_images/free.gif)
David W. Ayer PhD Vladimir Skljarevski MD Janet H. Ford PhD Allen W. Nyhuis MS Richard B. Lipton MD Sheena K. Aurora MD 《Headache》2018,58(8):1225-1235
Objective – To evaluate 12‐week changes from baseline of 2 disease‐specific patient‐reported outcome (PRO) measures in adults with migraine treated with galcanezumab, an investigational humanized antibody binding calcitonin gene‐related peptide (CGRP), or placebo. Background – Preventing headache‐related functional impairment is an important goal of migraine preventive treatment and a measurement target for PROs. Understanding which drugs have the potential to improve patient functioning in addition to preventing migraine headaches is vital to lessening patient burden. Design/Methods – This Phase 2b double‐blind, randomized, placebo‐controlled study enrolled adults with episodic migraine. Galcanezumab (120 mg subcutaneous injection; n = 60) or placebo (n = 127) was administered every 28 days for 12 weeks. Post hoc secondary analyses were conducted for those who completed 12 weeks of treatment on 2 PROs: The Migraine‐Specific Quality of Life Questionnaire (MSQ) v2.1 and the Headache Impact Test? (HIT‐6). Results – Analysis of covariance revealed significant differences in least square mean changes from baseline between galcanezumab and placebo for all MSQ domains including total mean change placebo of 18.63, galcanezumab of 27.36 (95% CI 2.449, 15.008; P‐value of .0067); Role Function‐Restrictive mean change placebo of 22.40, galcanezumab of 31.92 (95% CI 2.636, 16.518; P‐value of .0071); Role Function‐Preventive mean change placebo of 13.43, galcanezumab of 19.76 (95% CI 0.476, 12.185; P‐value of .0342); and Emotional Function mean change placebo of 16.88, galcanezumab of 26.61 (95% CI 2.789, 16.674; P‐value of .0063). At baseline, mean number of migraine headache days (MHDs) did not correlate with MSQ total scores or HIT‐6. At 12 weeks post‐treatment, MHD correlated with MSQ and HIT‐6 scores (all P < .0001). Change in MHD was associated with change in MSQ domains and change in HIT‐6 scores (all P < .0001). Conclusions – In comparison with placebo, treatment with galcanezumab was associated with significant functional improvements as reflected by changes in MSQ scores. Change in MHD was associated with improvements in MSQ and reductions in HIT‐6 scores, indicating the clinical importance of these changes in relation to PROs that measure function. 相似文献
95.
96.
Marcelo E Bigal Sarah Walter Alan M Rapoport 《British journal of clinical pharmacology》2015,79(6):886-895
CGRP is an extensively studied neuropeptide that has been implicated in the pathophysiology of migraine. While a number of small molecule antagonists against the CGRP receptor have demonstrated that targeting this pathway is a valid and effective way of treating migraine, off-target hepatoxicity and formulation issues have hampered the development for regulatory approval of any therapeutic in this class. The development of monoclonal antibodies to CGRP or its receptor as therapeutic agents has allowed this pathway to be re-investigated. Herein we review why CGRP is an ideal target for the prevention of migraine and describe four monoclonal antibodies against either CGRP or its receptor that are in clinical development for the treatment of both episodic and chronic migraine. We describe what has been publically disclosed about their clinical trials and future clinical development plans. 相似文献
97.
Familial migraine and coronary artery spasm in two siblings 总被引:2,自引:0,他引:2
A common pathophysiology for the clinical association of variant angina and migraine has been suggested, but the pathogenesis of both illnesses is yet unknown. Our report presents two siblings with both illnesses and a familial history of migraine where coronary artery spasm was documented, spontaneously in one and after the administration of ergonovine maleate in the other one. Our study strongly supports the hypothesis that genetic factors possibly play a role in the etiology of variant angina and migraine at least in some patients. 相似文献
98.
Headache is regarded by patients as a disturbing (or unpleasant) symptom. It can be produced by either organic diseases or functional head abnormalities. Twenty-five years ago headache was supposed to be a psychosomatic angiospastic algia. Certain unusual forms were thought to be caused by triggers like anger, cough, exertion, and sexual activity. Experimental research explored the role of circulating serotonin, prostaglandin, estrogen levels, and platelet abnormalities. As computed tomography, helical computed tomography, and scanning or magnetic resonance imaging evolved, new data became available. None of the newer reports have demonstrated liver involvement as a cause of headache. This minireview intends to cover the spectrum of brain alteration in liver disease. It describes some of the pathophysiological characteristics of hepatic encephalopathy and, also, the relationship among migraine, constipation, and liver disease. 相似文献
99.